Immunotherapy Combination for BRAF+ Melanoma - NCI
WEBDec 17, 2021 · Results from a large study are expected to help determine the best treatment approach for some people with an advanced form of melanoma. The NCI-sponsored clinical trial, called DREAMseq, included people with metastatic melanoma whose tumors had a specific mutation in the BRAF gene, called V600.
BRAF in malignant melanoma progression and metastasis: …
WEBApr 1, 2020 · This review delineates the current role of BRAF in melanoma progression and metastasis. It discusses targeted therapies and resistance mechanisms to BRAF inhibitors, and illustrates strategies to overcome this …
BRAF Gene and Melanoma: Back to the Future - PMC
WEBMar 27, 2021 · BRAF V600-mutant patients treated with first-line anti-PD-1 and anti-CTLA-4 combination therapy reached better overall survival (5-years OS: 60% vs. 48%) than BRAF wild-type ones ; however, BRAF-mutant melanoma specimens have shown lower TMB values compared with wild-type ones, suggesting that factors other than neoantigen load are responsible ...
BRAF Mutations in Melanoma: Biological Aspects, Therapeutic ...
WEBAug 8, 2023 · BRAF-mutated melanomas display unique features: they tend to be more aggressive than BRAF wild-type (WT) melanomas, are more likely to metastasize to the brain, and are associated with shorter survival in patients with stage IV tumours .
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma …
WEBFeb 8, 2024 · About 50% of patients with melanoma will be BRAF wild-type, which limits currently approved therapeutic options to anti-PD-1, anti-CTLA4 and anti-Lag-3 monoclonal antibodies. Patients who progress on these agents are in need of additional options, many of which are currently being evaluated in preclinical models and early-phase clinical trials.
Wild-type KRAS is a novel therapeutic target for melanoma
WEBOct 23, 2017 · Malignant melanoma is one of the most deadly and most common types of cancer worldwide. 1 Until 2011, disseminated melanoma was treated inefficiently with cytotoxic agents that failed to...
Systemic treatment of metastatic melanoma lacking a BRAF …
WEBMar 14, 2024 · BRAF wild-type disease – Among the 95 patients with BRAF wild-type disease, TILs improved PFS over ipilimumab (HR 0.53, 95% CI 0.34-0.84). Further details of the efficacy of TILs in those with BRAF mutant metastatic melanoma are …
Treatment resistance to melanoma therapeutics on a single cell level
WEB3 days ago · Briefly, for cell lines from patient 762, at both lower metformin concentrations, significantly increased cell death was seen in the BRAF/MEK resistant cell line as compared to the wild type cell ...
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type ...
WEBSurvival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial.
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF ...
WEBSep 30, 2020 · In this multicenter, double-blind, phase III study, 418 patients with previously untreated, unresectable, stage III/IV, wild-type BRAF melanoma were randomly assigned 1:1 to receive nivolumab 3 mg/kg every 2 weeks or …